The Nordic region leads the world in gender equality, access to public health data and innovation capacity. So why does women’s health remain an underfunded and underserved market, even here? That was the starting point for one of the panels at BioStock Life Science Summit 2026, held in front of a packed room.
Moderated by Laura Bejtulai, Strategic Advisor in fundraising and operations, the panel brought together Julie Brogren, CEO of Gedea Biotech, Camilla Harder Hartvig, Group Leader Women’s Health and Life Science at Angella Invest, and Georgina Askeland, Principal at Hadean Ventures. The discussion looked at why the opportunity has been overlooked for so long, but even more at what could change it.
One reason is that capital follows exits, and women’s health has seen few of them in recent years. The field also still lacks key foundations, from epidemiology, preclinical models and standardised endpoints to clear regulatory guidance and, in some cases, a system willing to pay for new products. Generating the data needed will take an effort across the whole ecosystem, and opportunities must be presented with scalable economic models and in language that resonates with investors.
See the full panel discussion “The Women’s Health Investment Revolution: Unlocking a Nordic Opportunity” below.